Evidence map›Paper›PMID 40326251›Full record

ReviewRecent patents on nanotechnology2025

A Comprehensive Review on Recent Advances and Patents of Niosomes.

Sakshi Saharawat, Sushma Verma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sakshi SaharawatPharmacy Institute, Noida Institute of Engineering and Technology, Uttar Pradesh, Greater Noida, India.
Sushma VermaPharmacy Institute, Noida Institute of Engineering and Technology, Uttar Pradesh, Greater Noida, India.ORCID 0000-0002-7816-4625

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Niosomes are novel, self-assembled vesicular carriers that deliver both lipophilic and hydrophilic drugs at the specific site in a targeted way, enhancing bioavailability and extending therapeutic effects. Niosomes are a versatile drug delivery system with a diverse range of applications from gene to brain-targeted delivery and they are more attractive choices than liposomes as they are efficient at biodegrading. Niosome offers several advantages over conventional drug delivery systems, including enhanced stability, and also have gained a lot of focus in natural product delivery in recent years. This review provides a comprehensive view of niosomal research and recent advancements, including classification and fabrication methods, and their role in drug delivery and targeting. The description of the rise in niosomal formulation patents around the world is also elaborated along with the natural product delivery of niosomes which has recently gained significance. Patents on novel preparation, loading, and modification techniques have enhanced the importance of niosome in the pharmaceutical industry.

Indexed as

Drug CarriersDrug Delivery SystemsLiposomesPatents as TopicAnimalsHumansDrug CarriersLiposomesdrug deliverydrug targetingNiosomesnon-ionic surfactant systempatents.vesicular carriers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.